drugset / Trial / NCT04341727
Hydroxychloroquine,Hydroxychloroquine,Azithromycin in the Treatment of SARS CoV-2 Infection
RandomizedParallel-groupOpen-labelTreatment
Summary
This Phase III trial four treatment strategies non-critically ill hospitalized participants (not requiring intensive care unit (ICU) admission and/or mechanical ventilation) with SARS CoV-2 infection, Participants will receive hydroxychloroquine or chloroquine with or without azithromycin.
Timeline
- Start
- 2020-04-04
- Primary completion
- 2021-04-01
- Completion
- 2021-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Azithromycin | Small molecule | 250 mg | Oral |
| Comparator | Chloroquine | Small molecule | 500 mg | Oral |
| Comparator | Hydroxychloroquine | Small molecule | 200 mg | Oral |